Genvor Inc. Company Summary

Overview

Genvor Incorporated is a biotech company focused on developing sustainable crop protection and plant health solutions using proprietary peptide technology. The company aims to address major agricultural threats like plant pathogens, toxins, bacteria, and fungi, with the goal of reducing crop losses and increasing yields globally.

Technology and Product Focus

• Develops antimicrobial peptides (AMPs) and nutritionally enhanced peptides (NEPs).
• Uses peptides to bolster plant defenses against fungi, bacteria, viruses, and pests.
• Peptides can be delivered via:
  • Genetic seed traits (transgenic plants expressing AMPs internally)
  • Topical or foliar biological spray applications (bio-pesticides)
• Peptides are naturally derived and developed without toxic chemicals, offering environmentally friendly crop protection.
• The peptide platform is protected by US patents covering 24 proprietary peptides and an additional 16 pending peptides.

Applications and Market

• Major crops targeted include corn, soybeans, cotton, berries, cannabis, wheat, citrus, and peanuts.
• Focused on preventing aflatoxin contamination (notably from Aspergillus flavus in corn), which causes significant health and economic issues.
• Industry estimates crop losses due to plant disease exceed $220 billion annually.
• Genvor’s peptides have shown promise in reducing aflatoxin contamination by 70% in USDA testing.
• Technologies are being developed for:
  • Genetic seed trait incorporation (for continuous, internal expression in crops)
  • Bio-fungicide sprays for immediate protection
  • Nutritional improvements in animal feed (increased protein content in crops like corn and sweet potato)

Collaborations and Regulatory Pathways

• Partnership with USDA through a Cooperative Research and Development Agreement (CRADA), with ongoing studies for seed traits and crop protection.
• Awarded the Bayer Golden Ticket in 2024, providing resources to accelerate product development at Bayer’s innovation center.
• Business model emphasizes licensing and strategic partnerships rather than direct manufacturing, aiming for revenue generation via licensing royalties.
• Regulatory pathways focus on gaining approvals for seed traits and biological spray formulations.

Business Strategy

• Leverage R&D via external partnerships and government collaborations.
• Maintain a capital-efficient, "license-first" approach.
• No current revenue; expects to generate income starting at the end of 2025 through licensing and royalties.

Financial and Operational Highlights

• As of September 30, 2024:
  • Employees: 1 full-time employee
  • Revenue: $0 (no revenue reported for 2024 or 2023)
  • Net Loss: $2,884,958 in 2024
  • Total Assets: $35,580
  • Total Liabilities: $1,749,710
  • Shareholders’ Equity: -$1,714,130 (deficit)
  • Share Count: 29,634,608 common shares outstanding as of July 31, 2025
• The company has a working capital deficit of roughly $1.73 million.
• Revenue is not yet generated; the company is in the research and development stage with significant expenses in R&D, professional fees, and stock-based compensation.

Employees & Management

• As of September 30, 2024:
  • 1 full-time employee
  • Key officers include CEO Chad Pawlak, and scientific officers Dr. Clayton Yates and Dr. Jesse Jaynes.
• No independent directors; governance primarily managed by the existing board with no active committees.

Additional Notes

• The company’s operations are primarily R&D and licensing-based.
• No established trading market for shares; previously quoted on OTC Link ATS.
• No dividends paid; all earnings retained for development.
• The company is a shell company with emerging growth status and expects to develop and license its technologies rather than produce revenue immediately.